Docoh
Loading...

LOGC LogicBio Therapeutics

Employees

Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
LogicBio Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 11, 2021. The stockholders (i) elected three Class III directors to the Company’s Board of Directors (the “Board”) to serve until the 2024 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal; and (ii) ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.

(i) The Class III directors elected to the Board, as well as the number of votes for, votes withheld, abstentions and broker non-votes with respect to each of these individuals, are set forth below:

DirectorVotes ForVotes AgainstAbstentionsBroker Non-Votes
Frederic Chereau19,026,582698,86948,3028,088,772
Richard Moscicki, M.D.18,843,241881,88348,6298,088,772
Michael Wyzga14,894,2634,830,50448,9868,088,772


(ii) The proposal to ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 received the following votes:

Votes For:27,773,669
Votes Against:34,218
Abstentions:54,638
Broker Non-Votes: